{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:30:20Z","timestamp":1789576220502,"version":"build-2803163510"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","award":["2024ZD0527406"],"award-info":[{"award-number":["2024ZD0527406"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373662"],"award-info":[{"award-number":["82373662"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973132"],"award-info":[{"award-number":["81973132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["IS24047"],"award-info":[{"award-number":["IS24047"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec010\">\n<jats:title>Background<\/jats:title>\n<jats:p>Current guidelines for statin use in primary prevention of cardiovascular disease (CVD) predominantly rely on absolute 10-year CVD risk scores. However, this approach may not adequately capture heterogeneity in the potential benefit of low-density lipoprotein cholesterol (LDL-C) reduction. This study compares the absolute risk-based approach with an individualized benefit approach, based on the Causal-Benefit model considering predicted lipid-lowering effects, for statin eligibility in Chinese populations.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec011\">\n<jats:title>Methods and Findings<\/jats:title>\n<jats:p>We analyzed nationally representative data from the China Health and Retirement Longitudinal Study, including adults aged 40\u201380 years, free of diabetes and CVD history, with LDL-C levels between 1.8 mmol\/L and 4.9 mmol\/L, and no prior statin use. Statin eligibility was determined using two strategies: (i) the absolute risk-based approach (10-year CVD risk), and (ii) the individualized benefit approach (using the Causal-Benefit model framework incorporating predicted individual absolute risk reduction [iARR]). We estimated eligible populations, CVD events averted, and number needed to treat (NNT) both at population and individual level (iNNT) over 10 years versus no treatment, assessed discordance, and primarily calibrated the benefit threshold to match event prevention by the risk-based approach for comparison. A total of 7,287 adults were analyzed, forming a cohort reflective of 324.6 million Chinese adults (mean age 57 years; 51.7% women). To prevent a similar number of CVD events (2.19 million <jats:italic>vs.<\/jats:italic> 2.16 million), 49.2 million (95% confidence interval [CI]: 45.3,53.0) and 50.3 million (95% CI: 46.0,54.6) adults would be eligible for statins therapy under the individualized benefit and absolute risk-based approaches, respectively. Among 58.9 million adults eligible for either strategy, the concordance was only 68.9%. The benefit approach alone identified 8.6 million people highly benefit from statin therapy, who would not be eligible for statin therapy under the absolute risk-based approach, and this includes 1.3 million people with borderline risk (5% to 7.5%). Conversely, the risk-based approach selected more individuals with low predicted benefit (minimum iARR: 2.5% <jats:italic>vs.<\/jats:italic> 3.4%), resulting in a less efficient individual-level targeting profile (maximum iNNT: 41 <jats:italic>vs.<\/jats:italic> 29). A key limitation of this study is that benefit was estimated primary from LDL-C reduction, which may neglect other biological mechanisms of statin effects and underestimate the total benefit.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec012\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The individualized benefit approach prioritizes individuals most likely to benefit from statin therapy, differing from conventional risk-based selection through its superior individual-level precision. This approach can enhance the capacity to discriminate treatment effects at the individual level, making it particularly valuable for shared decision-making in resource-constrained settings.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004556","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:30:23Z","timestamp":1753205423000},"page":"e1004556","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Absolute risk-based versus individualized benefit approaches for determining statin eligibility in primary prevention of cardiovascular diseases in Chinese populations: A modeling study"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5304-3173","authenticated-orcid":true,"given":"Qiuping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3026-357X","authenticated-orcid":true,"given":"Minglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7524-485X","authenticated-orcid":true,"given":"Xiaofei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6990-0168","authenticated-orcid":true,"given":"Xun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-1290","authenticated-orcid":true,"given":"Pei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"pmed.1004556.ref001","first-page":"1028","article-title":"Cardiovascular disease risk assessment and reduction: summary of updated NICE guidance","volume":"381","author":"Guideline Committee","year":"2023","journal-title":"BMJ"},{"issue":"8","key":"pmed.1004556.ref002","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement","volume":"328","author":"Force US Preventive Services Task","year":"2022","journal-title":"JAMA"},{"issue":"34","key":"pmed.1004556.ref003","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"FLJ Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"pmed.1004556.ref004","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"GJ Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"10","key":"pmed.1004556.ref005","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"201974","author":"DK Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"pmed.1004556.ref006","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jamacardio.2022.1883","article-title":"Time to revisit using 10-year risk to guide statin therapy","volume":"7","author":"AM Navar","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"3","key":"pmed.1004556.ref007","article-title":"Primary prevention of cardiovascular disease: the past, present, and future of blood pressure- and cholesterol-lowering treatments","volume":"15","author":"MJG Leening","year":"2018","journal-title":"PLoS Med"},{"issue":"30","key":"pmed.1004556.ref008","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/eurheartj\/ehac268","article-title":"Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy","volume":"43","author":"S Li","year":"2022","journal-title":"Eur Heart J"},{"issue":"10226","key":"pmed.1004556.ref009","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","article-title":"Modifiable risk factors, cardiovascular disease, and mortality in 155\u2008722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study","volume":"395","author":"S Yusuf","year":"2020","journal-title":"Lancet"},{"issue":"16","key":"pmed.1004556.ref010","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1161\/CIRCULATIONAHA.115.018383","article-title":"Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease","volume":"133","author":"G Thanassoulis","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"pmed.1004556.ref011","doi-asserted-by":"crossref","first-page":"100825","DOI":"10.1016\/j.jacadv.2023.100825","article-title":"The causal-benefit model to prevent cardiovascular events","volume":"3","author":"C Kohli-Lynch","year":"2024","journal-title":"JACC Adv"},{"issue":"1","key":"pmed.1004556.ref012","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ije\/dys203","article-title":"Cohort profile: The China Health and Retirement Longitudinal Study (CHARLS)","volume":"43","author":"Y Zhao","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"3","key":"pmed.1004556.ref013","article-title":"Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: a cost-effectiveness modeling study","volume":"18","author":"C Li","year":"2021","journal-title":"PLoS Med"},{"issue":"11","key":"pmed.1004556.ref014","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/aje\/kwz170","article-title":"Venous blood-based biomarkers in the China health and retirement longitudinal study: rationale, design, and results from the 2015 wave","volume":"188","author":"X Chen","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"10","key":"pmed.1004556.ref015","article-title":"World health organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions","volume":"7","author":"WHO CVD Risk Chart Working Group","year":"2019","journal-title":"Lancet Glob Health"},{"key":"pmed.1004556.ref016","first-page":"100096","article-title":"Validating world health organization cardiovascular disease risk charts and optimizing risk assessment in China","volume":"8","author":"J Li","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"pmed.1004556.ref017","first-page":"102","article-title":"Risk stratification of atherosclerotic cardiovascular disease in Chinese adults","volume":"2","author":"X-L Yang","year":"2016","journal-title":"Chronic Dis Transl Med"},{"issue":"24","key":"pmed.1004556.ref018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"201973","author":"SM Grundy","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pmed.1004556.ref019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004316","article-title":"Population impact & efficiency of benefit-targeted versus risk-targeted statin prescribing for primary prevention of cardiovascular disease","volume":"6","author":"MJ Pletcher","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"pmed.1004556.ref020","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/eurheartj\/ehu004","article-title":"Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects","volume":"35","author":"J van der Leeuw","year":"2014","journal-title":"Eur Heart J"},{"key":"pmed.1004556.ref021","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2622","article-title":"Statistics notes: bootstrap resampling methods","volume":"350","author":"JM Bland","year":"2015","journal-title":"BMJ"},{"issue":"10062","key":"pmed.1004556.ref022","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)30388-9","article-title":"Guidelines for accurate and transparent health estimates reporting: the GATHER statement","volume":"388","author":"GA Stevens","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"pmed.1004556.ref023","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00134-014-3624-x","article-title":"Multiple imputation: a mature approach to dealing with missing data","volume":"41","author":"S Chevret","year":"2015","journal-title":"Intensive Care Med"},{"issue":"17","key":"pmed.1004556.ref024","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1161\/CIRCULATIONAHA.121.057631","article-title":"Beyond 10-year risk: a cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease","volume":"145","author":"CN Kohli-Lynch","year":"2022","journal-title":"Circulation"},{"issue":"11","key":"pmed.1004556.ref025","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.amjcard.2018.02.011","article-title":"Statin eligibility in primary prevention: from a risk-based strategy to a personalized approach based on the predicted benefit","volume":"121","author":"FHY Cesena","year":"2018","journal-title":"Am J Cardiol"},{"issue":"12","key":"pmed.1004556.ref026","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events","volume":"6","author":"Y Zhang","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"10","key":"pmed.1004556.ref027","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","article-title":"The LDL cumulative exposure hypothesis: evidence and practical applications","volume":"21","author":"BA Ference","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"pmed.1004556.ref028","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/jamacardio.2018.3476","article-title":"A long-term benefit approach vs standard risk-based approaches for statin eligibility in primary prevention","volume":"3","author":"G Thanassoulis","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"14","key":"pmed.1004556.ref029","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/eurjpc\/zwae174","article-title":"Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions","volume":"31","author":"SHJ Hageman","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"pmed.1004556.ref030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/eurheartj\/ehad539","article-title":"Recommendations for statin management in primary prevention: disparities among international risk scores","volume":"45","author":"GBJ Mancini","year":"2024","journal-title":"Eur Heart J"},{"issue":"17","key":"pmed.1004556.ref031","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/eurjpc\/zwad193","article-title":"Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease","volume":"30","author":"B Delabays","year":"2023","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"pmed.1004556.ref032","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamacardio.2019.2851","article-title":"Cost-effectiveness of low-density lipoprotein cholesterol level-guided statin treatment in patients with borderline cardiovascular risk","volume":"4","author":"CN Kohli-Lynch","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"12","key":"pmed.1004556.ref033","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jama.2024.12537","article-title":"Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations","volume":"332","author":"JA Diao","year":"2024","journal-title":"JAMA"},{"issue":"9753","key":"pmed.1004556.ref034","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"issue":"10059","key":"pmed.1004556.ref035","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"R Collins","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"pmed.1004556.ref036","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.tcm.2019.01.001","article-title":"Effect of statins on atherosclerotic plaque","volume":"29","author":"SO Almeida","year":"2019","journal-title":"Trends Cardiovasc Med"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:30:33Z","timestamp":1753205433000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004556"}},"subtitle":[],"editor":[{"given":"Andre P","family":"Kengne,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004556","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}